Veratis Advisors
PRME icon

Veratis Advisors’s Prime Medicine PRME Stock Holding History

Veratis Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$32.9K Buy
+10,758
New +$35.7K 0.02% 84

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Greenwich Wealth Management
Greenwich Wealth Management Greenwich, Connecticut $3.09B AUM 22.23% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Veratis Advisors's PRME Position: Q3 2026 in Review

Veratis Advisors opened a new position in Prime Medicine (PRME) in Q3 2026: 10,758 shares worth $32.9K. The stake represents 0.02% of the portfolio and ranks #84 among its holdings.

88 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Veratis Advisors held 10,758 shares of Prime Medicine worth $32.9K as of Q3 2026.
  • Prime Medicine was a new Veratis Advisors position in Q3 2026.
  • Prime Medicine made up 0.02% of Veratis Advisors's portfolio in Q3 2026, its #84 holding.
  • 88 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Veratis Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.